Beyond the Biological Clock: Eight Conversations About Fertility, Aging, and Longevity
Week 4 of 8 | Sunday, November 15, 2026
What if a simple blood test could tell you how many fertile years you have left?
Imagine visiting your physician at age 30 and receiving a report that tells you not only your chronological age but also your ovaries’ biological age.
Wouldn’t it be wonderful to know whether your reproductive system is aging faster or slower than expected?
And what if that information could help you make decisions about when to have children—or how to protect your fertility?
These possibilities are attracting considerable scientific interest.
But how close are we to making them a clinical reality?
As an obstetrician-gynecologist with more than 35 years of experience, I have seen remarkable advances in reproductive medicine. We can now assess ovarian reserve, evaluate reproductive hormones, and use sophisticated technologies to investigate infertility.
Yet one of the most important questions remains surprisingly difficult to answer:
How much reproductive time does an individual woman actually have left?
The answer requires us to distinguish between ovarian reserve, reproductive potential, and biological aging.
They are related, but they are not the same thing.
1. Chronological Age Versus Reproductive Age
In the first blog of this series, we explored the difference between chronological and biological age.
Chronological age tells us how long we have lived.
Biological age attempts to describe how our cells, tissues, and organs are functioning relative to expected aging patterns.
Reproductive aging adds another dimension.
Women are born with a finite population of oocytes. Over time, both the quantity and quality of the remaining eggs decline.
However, the rate of decline varies among individuals.
Two women of the same chronological age may have very different ovarian reserve measurements.
Does this mean one has a younger reproductive system?
Possibly in terms of certain ovarian characteristics, but we need to be careful.
A woman with a higher ovarian reserve does not necessarily have better-quality eggs, and a woman with a lower ovarian reserve is not necessarily infertile.
This distinction is fundamental to understanding the limitations of current fertility testing.
2. AMH: What Does It Really Tell Us?
Anti-Müllerian hormone, or AMH, is produced by granulosa cells in developing ovarian follicles.
Because AMH levels are associated with the number of small growing follicles, measuring AMH can provide an estimate of ovarian reserve.
It has become one of the most commonly requested fertility-related blood tests.
But what does a low AMH actually mean?
According to the American Society for Reproductive Medicine (ASRM), ovarian reserve testing is useful primarily for predicting ovarian response to stimulation during assisted reproductive treatment.¹
AMH can help clinicians anticipate whether a woman may produce relatively few or many eggs during an IVF cycle.
However, AMH is a poor standalone predictor of natural fertility.
A low AMH level does not necessarily mean a woman cannot conceive naturally.
Conversely, a high AMH level does not guarantee fertility.
This is an important message because women are increasingly ordering fertility tests directly, sometimes without adequate counseling.
I worry that some women receive results suggesting diminished ovarian reserve and conclude that pregnancy is no longer possible.
Others receive reassuring results and assume they can safely postpone childbearing.
Neither conclusion is justified by AMH alone.
AMH measures an aspect of ovarian reserve. It does not measure the number of fertile years remaining.
3. Antral Follicle Count: Another Piece of the Puzzle
Antral follicle count, or AFC, is measured using transvaginal ultrasound.
It estimates the number of small antral follicles visible in the ovaries, usually measuring approximately 2–10 mm.
Like AMH, AFC helps predict ovarian response during fertility treatment.
It is particularly useful when planning ovarian stimulation for IVF or egg freezing.
However, AFC has similar limitations.
It does not directly measure egg quality, predict the precise timing of menopause, or reliably determine an individual’s likelihood of natural conception.
A woman may have a relatively low AFC and still conceive naturally.
A woman with a high AFC may experience infertility for reasons unrelated to ovarian reserve.
These measurements are valuable clinical tools, but they are not crystal balls.
4. Can We Predict Menopause?
Researchers have investigated whether AMH measurements can help predict the timing of menopause.
Because AMH generally declines as women approach menopause, it seems reasonable that lower levels might indicate a shorter remaining reproductive lifespan.
A systematic review and individual participant data meta-analysis published in The Journal of Clinical Endocrinology & Metabolism examined whether AMH could predict menopause.²
The researchers found that AMH added information beyond chronological age when estimating the timing of menopause.
However, prediction intervals for individual women remained too wide to provide precise forecasts.
This distinction matters.
A test may be statistically associated with menopause timing across a population without being sufficiently accurate to guide an individual woman’s family-planning decisions.
Even if we could predict menopause accurately, that would not tell us precisely when natural fertility would decline.
Fertility typically decreases substantially before menopause occurs.
Predicting menopause and predicting the end of natural fertility are two different challenges.
5. The Rise of Epigenetic Clocks
One of the most exciting developments in longevity science involves epigenetic clocks.
Epigenetics refers to changes in gene regulation that occur without altering the underlying DNA sequence.
DNA methylation is one of the best-studied epigenetic mechanisms.
In 2013, researcher Steve Horvath described a method of estimating age using DNA methylation patterns across multiple tissues.³
Since then, researchers have developed additional epigenetic clocks intended to estimate biological aging and, in some cases, predict age-related health outcomes.
These technologies have generated enormous interest.
But could we use similar approaches to measure reproductive aging?
Scientists are investigating whether molecular changes in ovarian tissue, blood, and other biological samples might help characterize reproductive aging more accurately.
The possibility is fascinating.
A molecular test that could reliably identify accelerated reproductive aging before conventional markers become abnormal might eventually change preventive reproductive care.
However, there are important limitations.
Most established epigenetic clocks were not designed to predict ovarian reserve, egg quality, natural conception, or menopause.
A blood-based biological-age result should not be interpreted as a direct measurement of ovarian age.
And although ovarian-specific molecular clocks are being investigated, they are not yet validated for routine clinical decision-making.
6. What About Egg Quality?
One of the greatest limitations of current ovarian reserve testing is that it tells us relatively little about egg quality.
Egg quality is particularly important because the risk of chromosomal abnormalities increases with advancing maternal age.
This reflects, in part, age-related changes in meiotic processes and chromosome segregation.
Mitochondrial function, cellular metabolism, oxidative stress, and other mechanisms are also being studied in relation to oocyte aging.
But we currently lack a reliable, noninvasive clinical test that can determine the quality of a woman’s remaining eggs.
Neither AMH nor AFC can do this.
This is why chronological age remains such an important predictor of reproductive outcomes.
A woman aged 40 with a high AMH does not necessarily have the same reproductive prospects as a woman aged 28 with a similar AMH.
The quantity of remaining follicles and the developmental competence of the oocytes are different biological questions.

7. Are There New Reproductive Aging Clocks on the Horizon?
Researchers are exploring several promising approaches.
These include molecular biomarkers, epigenetic signatures, proteomic patterns, metabolomic measurements, and genetic factors associated with reproductive lifespan.
A major genome-wide association study published in Nature in 2021 identified hundreds of genetic signals associated with the timing of menopause.⁴
Many implicated pathways involved DNA damage response and repair.
These findings are particularly interesting because maintaining genomic integrity is also a major theme in biological aging research.
Could the mechanisms influencing ovarian aging also tell us something about aging elsewhere in the body?
Possibly.
But genetic associations do not mean that we can accurately predict an individual’s fertility or reproductive lifespan using a commercial genetic test.
Nor do they establish that changing these pathways will safely extend fertility.
For now, these discoveries are helping researchers understand the biology of reproductive aging rather than providing clinically validated reproductive countdown clocks.
8. What About the Male Reproductive Clock?
Men also experience reproductive aging, although the pattern differs from that in women.
Unlike women, men generally continue producing sperm throughout adulthood.
However, advancing paternal age is associated with changes in semen parameters, sperm DNA integrity, and certain reproductive outcomes.
Research has also demonstrated that the number of new mutations passed from fathers to children increases with paternal age.⁵
This does not mean that older men cannot father healthy children.
Most children born to older fathers are healthy.
But it challenges the assumption that male fertility remains biologically unchanged throughout life.
There is currently no validated clinical test that provides a man’s overall reproductive biological age or predicts how many fertile years he has remaining.
Semen analysis provides useful information about sperm concentration, motility, and morphology, but it is not a comprehensive measure of reproductive aging.
As with women, reproductive age is more complex than any single laboratory value.
9. Should Everyone Have Their Reproductive Age Tested?
This is where I believe we need to be particularly thoughtful.
The growing popularity of fertility testing reflects something positive: people want to understand their reproductive health before problems arise.
I strongly support earlier fertility education.
But education and testing are not interchangeable.
For someone with irregular menstrual cycles, a history of ovarian surgery, chemotherapy exposure, or other risk factors, appropriate reproductive evaluation may be valuable.
For someone considering IVF or egg freezing, AMH and AFC can help guide treatment planning.
However, routine ovarian reserve testing in women without infertility or relevant risk factors is not recommended as a general screening tool to predict future fertility.¹
A test should be ordered because it can answer a meaningful clinical question—not simply because it is available.
We also need to consider the psychological consequences of testing.
An abnormal result can create unnecessary anxiety.
A reassuring result can create false confidence.
Both can influence major life decisions.
10. The Future: From Measuring Aging to Understanding It
The next frontier in reproductive longevity may involve combining multiple sources of information.
Imagine integrating reproductive history, hormone measurements, ultrasound findings, genetics, and validated molecular biomarkers into a more comprehensive assessment.
Such an approach might eventually help identify individuals at risk of accelerated reproductive aging.
It could also support research into interventions intended to preserve reproductive function.
But before these technologies become routine clinical tools, they must demonstrate accuracy, reproducibility, and meaningful clinical benefit.
We need prospective studies showing that the information improves decisions and outcomes.
A sophisticated test is not necessarily a useful test.
And measuring biological age is not the same as evidence that we can reverse aging.
What I Want Every Woman to Know
If there is one message I hope readers take away from this discussion, it is this:
Your AMH level is not your fertility destiny.
Neither is your antral follicle count.
These tests can provide valuable information, particularly in fertility treatment, but they cannot tell you exactly how much reproductive time remains.
Chronological age, reproductive history, menstrual patterns, underlying health conditions, and individual circumstances all matter.
Rather than waiting for a test to tell us that time is running out, we should encourage reproductive education much earlier.
We should also keep investing in research that may eventually help us understand reproductive aging more precisely.
This is a central theme of my book, Optimize Your Fertility Naturally: A Holistic Guide to Achieving a Healthy Pregnancy, and one I will explore further at LongevityFest 2026 in Las Vegas this December.
We are entering an exciting era as reproductive medicine and longevity science begin to intersect.
But as we embrace new technologies, we must remember the difference between what science can measure, what it can predict, and what it can actually change.
The reproductive clock may be more complex than we once imagined. Understanding it is the first step toward making better-informed decisions about our reproductive futures.
Coming Next Sunday
Can We Slow the Reproductive Clock? The Science of Lifestyle, Mitochondria, and Ovarian Aging
We hear increasingly about interventions that promise to preserve fertility, improve egg quality, or even rejuvenate the ovaries.
But which approaches have credible scientific evidence behind them?
Next week, we’ll explore nutrition, metabolic health, mitochondrial function, and emerging reproductive longevity interventions—and distinguish promising research from proven clinical benefits.
Join me each Sunday for Beyond the Biological Clock: Eight Conversations About Fertility, Aging, and Longevity, leading up to my presentation at LongevityFest 2026.
Dr. Marina OBGYN
Obstetrician-Gynecologist
Author of Optimize Your Fertility Naturally: A Holistic Guide to Achieving a Healthy Pregnancy
References
- Practice Committee of the American Society for Reproductive Medicine, “Testing and Interpreting Measures of Ovarian Reserve: A Committee Opinion,” Fertility and Sterility 114, no. 6 (2020): 1151–57. https://doi.org/10.1016/j.fertnstert.2020.09.134.
- Marije Depmann et al., “Does AMH Relate to Timing of Menopause? Results of an Individual Patient Data Meta-Analysis,” The Journal of Clinical Endocrinology & Metabolism 103, no. 10 (2018): 3593–3600. https://doi.org/10.1210/jc.2018-00724.
- Steve Horvath, “DNA Methylation Age of Human Tissues and Cell Types,” Genome Biology 14, no. 10 (2013): R115. https://doi.org/10.1186/gb-2013-14-10-r115.
- Katherine S. Ruth et al., “Genetic Insights into Biological Mechanisms Governing Human Ovarian Ageing,” Nature 596 (2021): 393–97. https://doi.org/10.1038/s41586-021-03779-7.
- Augustine Kong et al., “Rate of de Novo Mutations and the Importance of Father’s Age to Disease Risk,” Nature 488 (2012): 471–75. https://doi.org/10.1038/nature11396.